Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Our Donors
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Investigating Myelin Modulation by Psychoplastogens as a Novel Mechanism for Sustained Therapeutic Outcomes in Neuropsychiatric Disorders

Project Overview

Psychedelic drugs, known for their profound effects on perception, are showing promise as rapid and long-lasting treatments for depression. This is especially important given the increasing number of people diagnosed with depression and the high rates of resistance to current treatments. However, scientists must fully understand how these substances work in the brain to develop safe and effective therapies.

This study focuses on the role of myelination, a process in which nerve fibres are coated with a protective layer called myelin. Myelin is essential for efficient brain communication and affects various functions, including mood regulation. Research has shown that people with depression often have deficits in myelination, which may contribute to mood and cognitive impairments.

Our preliminary findings suggest that 2-Bromo-LSD (2-Br-LSD), a non-hallucinogenic derivative of LSD, can cause lasting behavioural effects in mice, similar to other psychedelics. We also found that this drug increases myelin thickness in a key brain region involved in mood regulation, the prefrontal cortex. Further analysis suggests that 2-Br-LSD strongly affects a type of brain cell called oligodendrocytes, which are responsible for producing myelin.

To better understand these effects, our research will explore three key questions: (1) Can psychedelics reverse myelination deficits in the adult brain? (2) Is myelination necessary for their antidepressant effects? (3) What are the biological mechanisms driving these changes? By using advanced techniques, such as electron microscopy and genetic tools, we aim to determine how psychedelics influence myelination and whether this contributes to their antidepressant properties.

By uncovering these mechanisms, our research could pave the way for innovative depression treatments that target brain myelination, offering hope to millions of individuals struggling with this condition.

Principal Investigator

Argel Aguilar Valles , Carleton University

Partners and Donors

Crabtree Foundation

Project Ongoing

Investigating Myelin Modulation by Psychoplastogens as a Novel Mechanism for Sustained Therapeutic Outcomes in Neuropsychiatric Disorders

  • Grant Type

    Capacity building grants

  • Area of research

    Mental Health

  • Disease Area

    Mental illness

  • Competition

    Future Leaders in Canadian Brain Research

  • Province

    Ontario

  • Start Date

    2025

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2026 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co